Skip to main content

Table 6 Multivariate adjusted relative risk (RR)* and 95% confidence intervals (CI) for the association of light physical activity during four periods of life with breast cancer tumor characteristics: 118,899 postmenopausal women in the NIH-AARP Diet and Health Study

From: Intensity and timing of physical activity in relation to postmenopausal breast cancer risk: the prospective NIH-AARP Diet and Health Study

Light activity ER-
positive
†RR 		95%
CI 		ER-
negative
RR 		95%
CI 		p†† ER-
unknown
RR 		95%
CI 		p§ Invasive
RR 		95%
CI 		In
situ
RR 		95%
CI 		p£
Ages 15-18 years                   
   Never/Rarely 1.00 (ref.)    1.00 (ref.)     1.00 (ref.)     1.00 (ref.)    1.00 (ref.)    
   <1 hour/week 0.99 0.75 1.29 1.03 0.56 1.90   1.28 1.03 1.60   1.14 0.97 1.35 0.90 0.63 1.27  
   1-3 hours/week 0.97 0.78 1.21 1.07 0.65 1.74   1.10 0.91 1.33   1.04 0.91 1.20 1.06 0.81 1.39  
   4-7 hours/week 1.06 0.86 1.31 1.11 0.68 1.81   1.13 0.94 1.36   1.10 0.96 1.26 0.99 0.75 1.30  
   >7 hours/week 1.09 0.89 1.33 1.02 0.64 1.62 0.79 1.13 0.95 1.35 0.90 1.10 0.97 1.26 0.81 0.62 1.06 0.03
Ages 19-29 years                   
   Never/Rarely 1.00 (ref.)    1.00 (ref.)     1.00 (ref.)     1.00 (ref.)    1.00 (ref.)    
   <1 hour/week 1.20 0.88 1.66 0.88 0.41 1.87   1.09 0.82 1.46   1.12 0.91 1.37 1.48 0.94 2.32  
   1-3 hours/week 1.11 0.85 1.45 0.91 0.50 1.66   1.05 0.83 1.33   1.06 0.89 1.26 1.38 0.94 2.04  
   4-7 hours/week 1.00 0.77 1.31 1.04 0.59 1.86   1.17 0.93 1.48   1.09 0.92 1.29 1.31 0.90 1.92  
   >7 hours/week 0.99 0.77 1.27 1.04 0.59 1.86 0.99 1.14 0.91 1.42 0.00 1.06 0.90 1.25 1.15 0.79 1.66 0.91
Ages 35-39 years                   
   Never/Rarely 1.00 (ref.)    1.00 (ref.)     1.00 (ref.)     1.00 (ref.)    1.00 (ref.)    
   <1 hour/week 1.07 0.77 1.50 1.14 0.46 2.84   1.21 0.90 1.65   1.15 0.92 1.43 1.26 0.80 1.99  
   1-3 hours/week 1.07 0.81 1.41 1.48 0.70 3.13   1.17 0.91 1.52   1.15 0.95 1.38 1.17 0.80 1.73  
   4-7 hours/week 0.91 0.69 1.19 1.44 0.69 3.00   1.12 0.87 1.44   1.04 0.87 1.25 1.07 0.73 1.57  
   >7 hours/week 0.89 0.68 1.16 1.48 0.72 3.02 0.20 1.20 0.94 1.53 0.18 1.08 0.91 1.28 0.94 0.65 1.37 0.52
Past 10 years                   
   Never/Rarely 1.00 (ref.)    1.00 (ref.)     1.00 (ref.)     1.00 (ref.)    1.00 (ref.)    
   <1 hour/week 1.20 0.86 1.69 0.35 0.14 0.92   1.24 0.94 1.64   1.14 0.93 1.41 1.50 0.95 2.38  
   1-3 hours/week 1.06 0.80 1.41 1.04 0.59 1.86   1.00 0.79 1.27   1.03 0.86 1.22 1.35 0.91 2.02  
   4-7 hours/week 1.19 0.90 1.57 0.94 0.53 1.66   1.11 0.88 1.40   1.12 0.95 1.33 1.24 0.83 1.84  
   >7 hours/week 0.92 0.70 1.22 0.80 0.45 1.40 0.65 1.07 0.85 1.35 0.53 0.99 0.84 1.17 1.11 0.75 1.63 0.61
No. cancer cases** 1352    263     1907     3522    736    
  1. * Relative risks adjusted for: age (continuous); race/ethnicity (white, black, Hispanic, Asian/Pacific Islander/American Indian); education level (<12 years or high school equivalent, 12 years or high school equivalent, post-high school vocational or technical training, some college, college graduate, post-graduate); smoking status (non-smoker, former, current); alcohol intake (grams/day, quintiles adjusted for total energy intake); family history of breast cancer (no, yes); age at menarche (<13, 13-14, ≥ 15 years); age at first birth (nulliparous, <20, 20-24, 25-29, 30+ years); parity (number of children: 0, 1-2, 3 or more); age at menopause (<40, 40-44, 45-49, 50-54, ≥ 55 years); menopausal hormone use (never, ever)
  2. ** Total numbers of cancer cases may vary due to missing physical activity values.
  3. † ER: estrogen receptor. Hormone receptor status limited to invasive cancers.
  4. †† p-value for heterogeneity comparing RR for >7 hours/week of physical activity: ER-positive and ER-negative tumors.
  5. §p-value for heterogeneity comparing RR for >7 hours/week of physical activity: ER-positive, ER-negative, and ER-unknown tumors.
  6. £ p-value for heterogeneity comparing RR for >7 hours/week of physical activity: invasive and in situ tumors
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us

\